Nano Oncologicals
“Providing nanotherapeutic solutions for currently “incurable” cancers”

Prof. MJ Alonso Research Lab

**Background**

Our Lab has more than a decade experience in the design of nanotechnologies intended to target anti-cancer drugs to the tumors and the lymphatics, widely reporting the potential of a variety of formulations to reduce the toxicity and enhance the efficacy of a number of anticancer drugs.

**Clinical Advisors & Collaborators**

- **Dr. Alberto Gabizón** (Shaare Zedek Medical Center, Israel)
- **Dr. Manuel Hidalgo** (BIDMC HumCancer Center, US)
- **Dr. Paola Allavena** (Humanitas, Italy)
- **Dr. Rafael López** (CHUS, Spain)

**Active Multi-Focal Delivery Platform**

**FUNCTIONALITY:**

- **Dual tissue targeting**: tumor cells and metastatic cells in lymphatics
- **Dual cell targeting**: cancer cells and tumor-associated macrophages (TAMs)

**INDICATIONS:**

Cancers with lymphatic metastatic spreading

**DEVELOPMENT STATUS**

- Extensive *in vivo* POC studies in clinically relevant tumor models, obtaining the best-in-class PK/PD data
- IP rights until 2031 (new patents under filling)
- Accelerating first-in-human studies:

---

**PHARMACEUTICAL PROFILE:**

- Small size (40-150 nm)
- Regulatory acceptable materials
- High reproducibility and versatility (different drugs)
- Easy to scale-up, simple and mild technology
- Freeze-dryable for final dosage form
- Stable under storage

**TUMOR**

Cancer cells

TAMs

LYMPHATICS

---

**nanomedTAB**

Nanomedicine Translation Advisory Board

**ENATRANS**

European Nanomedicine Translation Network